Kygevvi
Kygevvi ingredients
| Active ingredient | Strength |
|---|---|
| Doxecitine | 2 g/1 |
| Doxribtimine | 2 g/1 |
What Kygevvi is used for
The FDA lists the approved uses on the official label (below). In the EU, doxecitine;doxribtimine is approved as Kygevvi for:
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kygevvi
- Generic name
- Doxecitine and doxribtimine
- Made by
- UCB, Inc.
- Forms
- Powder, For Solution
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA219792
- On the US market since
- 2026
Official information
- MedlinePlus drug information (search for Doxecitine and doxribtimine)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kygevvi?
Kygevvi (Doxecitine and doxribtimine) is a specialist medicine made by UCB, Inc., approved by the US FDA.
What are the ingredients of Kygevvi?
Kygevvi contains Doxecitine (2 g/1); Doxribtimine (2 g/1).
Is Kygevvi approved in Europe?
The same active substance is approved in the EU as Kygevvi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA